Drug Trial Radar · NCT02425644
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,133
Actual
Start
Jun 4, 2015
Primary completion
May 16, 2019
Study completion May 16, 2019
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis
Conditions
- Multiple Sclerosis
Interventions
ponesimodDrug
film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
teriflunomideDrug
film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Confirmed Relapse RateTime frame: From randomization to end of study (Week 108)
Locations
162 sites in 28 countries. Site status is shown where the registry gives one.
Investigator Site 8045
Carlsbad, California
Investigator Site 8311
Pomona, California
Investigator Site 8036
Denver, Colorado
Investigator Site 8065
Ormond Beach, Florida
Investigator Site 8018
Tampa, Florida
Investigator Site 8013
Indianapolis, Indiana
Investigator Site 8040
Raleigh, North Carolina
Investigator Site 8006
Columbus, Ohio
Investigator Site 8015
Franklin, Tennessee
Investigator Site 8042
Orem, Utah
Investigator Site 3605
Grodno, Belarus
Investigator Site 3603
Minsk, Belarus
Investigator Site 3602
Minsk, Belarus
Investigator Site 3606
Vitebsk, Belarus
Investigator Site 3604
Vitebsk, Belarus
Investigator Site 9104
Sarajevo, Bosnia and Herzegovina
Investigator Site 2709
Plovdiv, Bulgaria
Investigator Site 2711
Sofia, Bulgaria
Investigator Site 2702
Sofia, Bulgaria
Investigator Site 2707
Sofia, Bulgaria
Investigator Site 2701
Sofia, Bulgaria
Investigator Site 2708
Sofia, Bulgaria
Investigator Site 2703
Sofia, Bulgaria
Investigator Site 8102
Edmonton, Alberta, Canada
Investigator Site 8120
Victoria, British Columbia, Canada
Investigator Site 8101
Ottawa, Ontario, Canada
Investigator Site 8113
Greenfield Park, Quebec, Canada
Investigator Site 2506
Osijek, Croatia
Investigator Site 2502
Zagreb, Croatia
Investigator Site 2508
Zagreb, Croatia
Investigator Site 2509
Zagreb, Croatia
Investigator Site 3009
Brno, Czechia
Investigator Site 3003
Brno, Czechia
Investigator Site 3010
Hradec Králové, Czechia
Investigator Site 3006
Jihlava, Czechia
Investigator Site 3002
Ostrava-Poruba, Czechia
Investigator Site 3007
Pardubice, Czechia
Investigator Site 3001
Prague, Czechia
Investigator Site 3008
Prague, Czechia
Investigator Site 3004
Teplice, Czechia
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.